Walleye Capital LLC Lowers Stake in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Walleye Capital LLC reduced its stake in ANI Pharmaceuticals by 56.6%, selling 40,725 shares, leaving them with approximately 31,284 shares valued at $2,094,000.
• Several hedge funds have also increased their positions in ANI Pharmaceuticals, contributing to institutional ownership of 76.05% of the company's stock.
• Analyst ratings for ANI Pharmaceuticals have improved, with multiple firms upgrading the stock to a strong-buy rating and setting a consensus target price of $84.75.

Walleye Capital LLC lowered its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 56.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 31,284 shares of the specialty pharmaceutical company's stock after selling 40,725 shares during the period. Walleye Capital LLC owned about 0.14% of ANI Pharmaceuticals worth $2,094,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Millennium Management LLC grew its holdings in shares of ANI Pharmaceuticals by 89.3% during the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock valued at $55,437,000 after purchasing an additional 473,097 shares during the last quarter. Global Alpha Capital Management Ltd. boosted its position in ANI Pharmaceuticals by 17.8% during the 1st quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company's stock valued at $49,248,000 after buying an additional 111,040 shares during the period. Dimensional Fund Advisors LP boosted its position in ANI Pharmaceuticals by 4.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock valued at $37,906,000 after buying an additional 30,420 shares during the period. Deep Track Capital LP boosted its position in ANI Pharmaceuticals by 28.6% during the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after buying an additional 144,214 shares during the period. Finally, Aberdeen Group plc boosted its position in ANI Pharmaceuticals by 76.1% during the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company's stock valued at $28,059,000 after buying an additional 181,134 shares during the period. Institutional investors own 76.05% of the company's stock.

Insider Transactions at ANI Pharmaceuticals

In related news, Director Antonio R. Pera sold 5,421 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $89.73, for a total transaction of $486,426.33. Following the completion of the transaction, the director directly owned 29,952 shares of the company's stock, valued at $2,687,592.96. This trade represents a 15.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Muthusamy Shanmugam sold 52,988 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $90.44, for a total transaction of $4,792,234.72. Following the transaction, the chief operating officer directly owned 431,920 shares of the company's stock, valued at approximately $39,062,844.80. This trade represents a 10.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 405,538 shares of company stock worth $35,690,131. 12.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Zacks Research raised shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Guggenheim reissued a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Truist Financial increased their price target on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research report on Monday, August 11th. Finally, HC Wainwright reissued a "buy" rating and set a $93.00 price target (up previously from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $84.75.

ANI Pharmaceuticals Trading Up 1.0%

Shares of NASDAQ:ANIP traded up $0.97 on Friday, hitting $93.50. The company had a trading volume of 283,240 shares, compared to its average volume of 749,580. The firm's 50-day simple moving average is $73.39 and its two-hundred day simple moving average is $67.12. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $93.72. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -121.43 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $211.37 million during the quarter, compared to analysts' expectations of $187.18 million. During the same period last year, the company posted $1.02 EPS. The company's quarterly revenue was up 53.2% compared to the same quarter last year. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.